Wall Street Zen upgraded shares of Nuwellis (NASDAQ:NUWE – Free Report) to a hold rating in a research note released on Saturday morning.
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Nuwellis in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.
Get Our Latest Stock Report on Nuwellis
Nuwellis Trading Down 3.1%
Nuwellis (NASDAQ:NUWE – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($73.15) EPS for the quarter, missing analysts’ consensus estimates of ($35.00) by ($38.15). Nuwellis had a negative net margin of 214.90% and a negative return on equity of 32,351.83%. The business had revenue of $2.40 million for the quarter, compared to analysts’ expectations of $2.09 million.
Hedge Funds Weigh In On Nuwellis
A hedge fund recently raised its stake in Nuwellis stock. Sabby Management LLC raised its position in Nuwellis, Inc. (NASDAQ:NUWE – Free Report) by 149.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 89,685 shares of the company’s stock after acquiring an additional 53,791 shares during the period. Nuwellis makes up approximately 0.2% of Sabby Management LLC’s holdings, making the stock its 18th biggest holding. Sabby Management LLC owned 4.80% of Nuwellis worth $156,000 at the end of the most recent quarter. 3.13% of the stock is owned by institutional investors.
Nuwellis Company Profile
Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.
The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.
Recommended Stories
- Five stocks we like better than Nuwellis
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.
